Is brigatinib/brigatinib a targeted drug?

Yes,Brigatinib/Brigatinib (Brigatinib) is a targeted drug. It belongs to a class of tyrosine kinase inhibitors (TKI). It inhibits the growth and spread of tumor cells by specifically inhibiting targets in cancer cells and blocking the activation of abnormal signaling pathways. Brigatinib/Brigatinib is mainly used to treat specific types of non-small cell lung cancer (NSCLC), especially ALK (anaplastic lymphoma kinase) fusion-positive NSCLC. ALKfusion protein is an abnormal protein produced by the fusion of the ALK gene with other genes. It is more common in NSCLC patients. Brigatinib/Brigatinib inhibits the activity of ALK fusion protein and interferes with abnormal signaling, thereby inhibiting the proliferation and spread of tumor cells.